Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pamiparib (Primary) ; Temozolomide (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 30 Sep 2019 According to a BeiGene media release, as of July 29, 2019, a total of 113 patients with solid tumors have been enrolled in the study.
    • 30 Sep 2019 Results presented in a BeiGene Media Release.
    • 30 Sep 2019 According to a BeiGene media release, data were presented at the European Society for Medical Oncology (ESMO) Congress 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top